KARLSRUHE, Germany, March 4, 2011 /PRNewswire/ -- The High Court of Germany (Bundesgerichtshof) handed down a final ruling in favor of AmniSure® International, LLC in its dispute with the Finnish company Medix Biochemica. The court upheld the German Patent Court's ruling that the patent associated with Medix's ActimPROM test is null and void due to its lack of an inventive step. Medix is expected to pay AmniSure® an undisclosed amount to be determined by the courts.
"We are extremely pleased with the decision of the German High Court," said Dr. Michael Friedman, President and CEO of AmniSure® International. "The Court's decision coincided with the publication of the new peer-reviewed Guidelines of the European Association of Perinatal Medicine, which hailed the AmniSure® test as the 'most useful tool' and the 'most accurate bedside test' for diagnosing ruptured fetal membranes(1). The Court's decision closes a chapter for us by bringing a seven-year-long litigation, initiated by Medix, to its rightful conclusion. The publication of the European Guidelines, meanwhile, opens a new chapter for us by establishing the AmniSure® test as the new benchmark for diagnosing ruptured fetal membranes."
(1) The Journal of Maternal-Fetal and Neonatal Medicine, March 2011. ISSN 1476-7058
About AmniSure® International, LLC
AmniSure® International, LLC (http://www.amnisure.com) is a medical device company that operates internationally with headquarters in Boston, MA. AmniSure® International pioneered a rapid diagnostic device, AmniSure® ROM Test, which solves a long-standing problem in obstetrics and is rapidly becoming a new global standard in maternal fetal medicine.
This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.
SOURCE AmniSure International, LLC